Oncopeptides AB (ST:ONCO) — Stock Price

Skr1.59 SEK
▼ -0.75% today

Oncopeptides AB (ST:ONCO) is currently trading at Skr1.59 SEK, down 0.75% today. Over the past 52 weeks, shares have ranged between Skr1.27 and Skr6.16. This page tracks Oncopeptides AB's live share price on the ST exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see how much is Oncopeptides AB worth.

Oncopeptides AB (ONCO) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Oncopeptides AB's daily closing share price and trading volume on the ST exchange over the past year, giving a clear view of recent price momentum and liquidity.

Oncopeptides AB Income Statement — Revenue, Profit & Earnings by Year

Oncopeptides AB's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue Skr71.12 Million Skr31.65 Million Skr35.22 Million Skr8.36 Million Skr118.30 Million
Cost of Revenue Skr2.45 Million Skr2.66 Million Skr-1.08 Million Skr6.00K Skr53.12 Million
Gross Profit Skr68.67 Million Skr28.98 Million Skr36.30 Million Skr8.35 Million Skr65.17 Million
Research & Development Skr102.87 Million Skr121.19 Million Skr106.95 Million Skr217.66 Million Skr679.93 Million
SG&A Skr194.62 Million Skr60.84 Million Skr68.88 Million Skr84.09 Million Skr175.46 Million
Total Operating Expenses Skr297.49 Million Skr312.48 Million Skr289.75 Million Skr357.70 Million Skr1.49 Billion
Operating Income Skr-228.82 Million Skr-283.50 Million Skr-253.45 Million Skr-349.35 Million Skr-1.42 Billion
EBITDA Skr-228.82 Million Skr-261.81 Million Skr-231.62 Million Skr-319.62 Million Skr-1.40 Billion
EBIT Skr-271.55 Million Skr-242.66 Million Skr-336.80 Million Skr-1.42 Billion
Interest Expense Skr23.52 Million Skr12.66 Million Skr5.79 Million Skr883.00K Skr948.00K
Income Before Tax Skr-248.17 Million Skr-284.21 Million Skr-248.45 Million Skr-337.68 Million Skr-1.42 Billion
Income Tax Expense Skr1.42 Million Skr398.00K Skr664.00K Skr271.00K Skr8.95 Million
Net Income Skr-249.59 Million Skr-284.61 Million Skr-249.11 Million Skr-337.95 Million Skr-1.43 Billion

Oncopeptides AB Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Oncopeptides AB's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets Skr134.84 Million Skr244.19 Million Skr238.38 Million Skr385.32 Million Skr439.38 Million
Total Current Assets Skr117.16 Million Skr217.08 Million Skr202.90 Million Skr364.03 Million Skr412.37 Million
Cash & Equivalents
Short-term Investments Skr32.00K Skr348.00K Skr2.11 Million
Net Receivables Skr26.66 Million Skr11.14 Million Skr2.19 Million Skr17.27 Million Skr15.35 Million
Inventory Skr8.24 Million Skr4.37 Million Skr2.42 Million Skr0.00 Skr1.00
Property, Plant & Equipment Skr17.68 Million Skr27.11 Million Skr34.63 Million Skr20.44 Million Skr24.74 Million
Goodwill
Total Liabilities Skr193.73 Million Skr189.91 Million Skr181.60 Million Skr91.03 Million Skr228.51 Million
Total Current Liabilities Skr44.50 Million Skr51.35 Million Skr44.93 Million Skr85.67 Million Skr225.29 Million
Long-term Debt Skr126.68 Million Skr121.89 Million Skr106.49 Million Skr0.00
Net Debt Skr44.43 Million Skr-36.82 Million Skr-47.25 Million Skr-334.97 Million Skr-347.99 Million
Total Stockholder Equity Skr-58.89 Million Skr54.28 Million Skr56.78 Million Skr294.29 Million Skr210.87 Million
Retained Earnings Skr-5.90 Billion Skr-5.65 Billion Skr-5.37 Billion Skr-5.12 Billion Skr-4.78 Billion

Oncopeptides AB Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Oncopeptides AB generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow Skr-222.88 Million Skr-260.57 Million Skr-279.49 Million Skr-420.51 Million Skr-1.52 Billion
Capital Expenditures Skr0.00 Skr357.00K Skr116.00K Skr2.51 Million Skr339.00K
Free Cash Flow Skr-222.88 Million Skr-260.57 Million Skr-279.61 Million Skr-423.02 Million Skr-1.52 Billion
Investing Cash Flow Skr0.00 Skr496.00K Skr-116.00K Skr-2.51 Million Skr-339.00K
Financing Cash Flow Skr128.55 Million Skr263.81 Million Skr106.89 Million Skr392.40 Million Skr1.03 Billion
Dividends Paid Skr43.21 Million Skr82.46 Million
Stock-Based Compensation Skr9.49 Million Skr19.15 Million Skr-34.20 Million
Depreciation Skr9.67 Million Skr9.75 Million Skr11.04 Million Skr17.16 Million Skr14.99 Million
Change in Cash Skr-96.28 Million Skr5.13 Million Skr-171.11 Million Skr-17.67 Million Skr-478.07 Million

Oncopeptides AB Earnings History — EPS Actual vs. Analyst Estimates

Track Oncopeptides AB's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
May 13, 2026
Feb 20, 2026 -0.24
Nov 05, 2025 -0.24
Aug 21, 2025 -0.30
May 15, 2025 -0.29
Feb 27, 2025 -0.39
Nov 07, 2024 -0.29
Aug 14, 2024 -0.35